6-methyl-1H-indol-4-amine | 885520-81-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-methyl-1H-indol-4-amine
• CAS: 885520-81-0
• 化学式: C₉H₁₀N₂
• mdl: MFCD07781469
• 分子量: 146.19
• InChiKey: JGZBDXTVJJTZOR-UHFFFAOYSA-N

物化性质

• 沸点：
  347.4±22.0 °C(Predicted)
• 密度：
  1.213±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  41.8
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS
  申请人：Baker Stewart James

  公开号：US20100016306A1

  公开（公告）日：2010-01-21

  Thienopyrimidines of formula (Ia) or (Ib): wherein R 1 -R 3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

  式(Ia)或(Ib)的噻唑并[3,2-d]嘧啶类化合物：其中R1-R3具有以下任何一种所述的值，以及其药学上可接受的盐具有PI3K抑制剂活性，因此可用于治疗由于PI3激酶异常细胞生长、功能或行为引起的疾病和障碍，特别是p110 delta亚型，例如免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌障碍和神经障碍。还描述了合成该化合物的方法。
• PHARMACEUTICAL COMPOUNDS
  申请人：Baker Stewart James

  公开号：US20120283257A1

  公开（公告）日：2012-11-08

  Thienopyrimidines of formula (Ia) or (Ib): wherein R 1 -R 3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.

  公式（Ia）或（Ib）的噻唑嘧啶类化合物：其中R1-R3具有此处所述的任何值，其药学上可接受的盐具有PI3K抑制剂活性，因此可用于治疗由与PI3激酶相关的异常细胞生长、功能或行为引起的疾病和障碍，尤其是p110 delta亚型，如免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌障碍和神经障碍。还描述了合成这些化合物的过程。
• THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS
  申请人：Hancox Timothy Colin

  公开号：US20110021496A1

  公开（公告）日：2011-01-27

  Thienopyrimidines of formula (I) wherein W and R 1 to R 4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.

  公式（I）中，W和R1至R4的定义如索权所述，其药学上可接受的盐是PI3K的抑制剂，并且选择性地作用于p110δ同工酶，该同工酶是一种Ia类PI3激酶，优于其他Ia类和Ib类激酶。这些化合物可用于治疗由PI3激酶引起的异常细胞生长、功能或行为所引起的疾病和障碍，如癌症、免疫障碍、心血管疾病、病毒感染、炎症、代谢/内分泌功能障碍和神经系统障碍。
• [EN] ATR INHIBITOR AND USE THEREOF<br/>[FR] INHIBITEUR D'ATR ET SON UTILISATION<br/>[ZH] ATR抑制剂及其用途
  申请人：CHENGDU EASTON BIOPHARMACEUTICALS CO LTD

  公开号：WO2022268025A1

  公开（公告）日：2022-12-29

  一类式I所示的具有ATR抑制作用的新化合物及其在制备药物中的用途。
• US8252792B2
  申请人：——

  公开号：US8252792B2

  公开（公告）日：2012-08-28